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Gastric cancer is a global health problem; although incidence rates are declining, it remains 
the third most common cause of cancer death worldwide.1   Gastric cancer patients with 
advanced disease have limited treatment options available, and most will live for less than 
two years, therefore exploration of gastric cancer disease biology is warranted to identify 
new targets.2     Recent comprehensive molecular analyses have identified distinct 
subgroups of gastric cancer which may have therapeutic relevance, however with the 
exception of microsatellite unstable tumours the potential for genomically guided therapy has 
not been realised.3-5 
In this edition of JAMA Oncology, Li and colleagues investigate the relationship between 
MUC16 mutation, tumour mutation load (TML) and survival in patients with gastric 
adenocarcinoma.6    Using data from the TCGA gastric cancer dataset and a second, 
smaller, Asian validation cohort, the investigators demonstrate that tumours which are 
MUC16 mutant are more likely to have a higher tumour mutation burden (p<0.001).   This 
association was independent of age, gender, and the presence of mutations in genes 
affecting genomic stability such as BRCA1/2 and POLE.  Independence from microsatellite 
instability (MSI) status could not be determined as MSI results were not available for every 
TCGA patient; however, the association between MUC16 mutation and TML also appeared 
to be independent of derived mismatch repair deficiency signatures.   Li et al then proceed to 
demonstrate that patients who have MUC16 mutant tumours have longer median overall 
survival than patients with a MUC16 wildtype tumour genotype.  In TCGA patients with 
resected gastric cancer the median overall survival was 26.7 months for MUC16 wildtype 
versus 46.9 months for MUC16 mutant tumours respectively (p=0.007); similar results were 
demonstrated in the Asian dataset.  This prognostic effect of MUC16 mutation on overall 
survival also remained statistically significant when adjusted for confounding factors.   
The findings presented by Li et al are interesting because if MUC16 mutation is truly 
predictive of high TML this could have clinical implications. The most readily apparent use of 
MUC16 mutation as a surrogate for TML would be to identify gastric cancer patients who 
might benefit from immune checkpoint blockade.   As only one in six patients with PD-L1 
selected gastroesophageal cancer respond to anti-PD-1 therapy, better enrichment 
biomarkers are a priority.7    Retrospective analysis across multiple cancer  types and clinical 
trials demonstrates a significant correlation between tumour mutational load and response to 
PD-1 inhibition.8    Prospectively in the Checkmate 577 study, non-small cell lung cancer 
patients with a high tumour mutation load (≥10 mutations per megabase) had significantly 
superior progression free survival when treated with nivolumab and ipilimumab compared to 
chemotherapy, independent of PD-L1 expression.9       The authors’ transcriptomic results 
support the suggestion that MUC16 mutation could predict for sensitivity to anti-PD-1 
therapy; MUC16 mutant gastric tumours are immunologically “hot”.   Most recently, tumour 
mutation load has been assessed using a commercially available next generation 
sequencing (NGS) panel.8,9   However, if TML assessment were to be reduced to MUC16 
sequencing only as a surrogate for a larger NGS panel, precise quantification of the 
relationship between MUC16 mutation and mutation rate per megabase in gastric cancer 
would be required to inform biomarker development.      
Clinical limitations of the current work include the small size, restricted ethnic make-up, and 
heterogeneous nature of the validation cohort.   The first major challenge to the scientific 
validity of the current work is the risk of a false positive association between MUC16 
mutation and high TML because of characteristics associated with MUC16.   MUC16 is a 
very large gene sited in an area with low replication timing.  Regions of low replication timing 
are more likely to accumulate frequent mutations.    Considering other relevant mutational 
co-variates, it is possible that MUC16 has a mutation rate which is in line with what might be 
expected by chance.    Secondly, correlation between MUC16 mutation and high TML does 
not necessarily imply causation; a functional explanation for the link between MUC16 
mutation and high TML is absent.   An alternative explanation for the improved long-term 
survival of MUC16 mutant patients in this study may not relate directly to tumour mutation 
load.  In an assessment of the tumour biology of long term survivors following pancreatic 
tumour resection, neoantigens (but not non-antigenic mutations) in MUC16 were identified 
four times more frequently in long term survivors than in patients who had shorter survival.10    
In vitro, MUC16 expression is associated with proliferation and metastatic potential in tumour 
cells, and MUC16 is also known to inhibit natural killer cell mediated lysis of tumours.11,12   
Thus, elimination of MUC16 neoantigen presenting cancer cells via immune “pruning” could 
hypothetically leave a residual population of MUC16 non-expressing cells with reduced 
metastatic and immunosuppressive potential, which could be associated with longer survival; 
this could present an alternative explanation for the authors’ transcriptomic results on 
immune infiltrate.    Data on MUC16 neoantigen presentation are not provided in the current 
manuscript; this should be a priority for future research.  
There is a paucity of evidence linking MUC16 gene function to cancer, therefore it is unlikely 
that MUC16 mutations are positively selected oncogenic drivers.   This makes the 
hypothesis that MUC16 mutations act through neoantigen presentation and immunoediting 
more plausible.     Despite the challenges in understanding the relationship between MUC16 
mutation and TML, the relationship with prognosis appears to be robust.   Although the 
results presented by Li and colleagues are preliminary and require further validation, they 
could provide a signpost for clinically relevant research in gastric cancer, or in view of the 
ubiquity of MUC16 mutations, in other tumour types.    
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